Loading
Gemcitabine + Ivonescimab / NSCLC (advanced Non Small Cell Lung Cancer) / Nsclc · Phase 2 Trial
ClinicalTrials.gov · August 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2 trial registration, not a published results report. The study is recruiting to evaluate ORR in 47 patients with advanced NSCLC resistant to prior chemoimmunotherapy, receiving gemcitabine plus ivonescimab. No efficacy or safety data are reported in this registry record.
Phase 2, Interventional, Single Group, Open label, Treatment purpose. NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer); age from 18 Years. Intervention: Gemcitabine + Ivonescimab in Advanced NSCLC Resistant to Im…. n = 47. 7 sites: Switzerland.
This is a Phase 2 trial registration, not a published results report. The study is recruiting to evaluate ORR in 47 patients with advanced NSCLC resistant to prior chemoimmunotherapy, receiving gemcitabine plus ivonescimab. No efficacy or safety data are reported in this registry record.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This trial addresses an unmet need in post-chemoimmunotherapy NSCLC by testing a mechanistically rational combination; however, clinicians should await reported results before considering this evidence for practice.
Phase 2 trial with surrogate endpoint (ORR) in a small, single-arm population; results not yet reported in this registry record.
As stated by the source record.
Quoted from the source exactly as published.
This trial addresses an unmet need in post-chemoimmunotherapy NSCLC by testing a mechanistically rational combination; however, clinicians should await reported results before considering this evidence for practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07158489). This is a study registration, not published results. Lead sponsor: Swiss Cancer Institute. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 47 participants (ESTIMATED). Conditions: NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer). Interventions: DRUG: Gemcitabine + Ivonescimab. Primary outcome measures: Objective response rate (ORR) according to RECIST v1.1 , At the end of trial treatment, up to 2 years from registration.. Brief summary: This Phase II clinical trial (investigates the efficacy of combining gemcitabine, a chemotherapy agent, with ivonescimab, a bispecific PD-1/VEGF antibody, in patients with advanced non-small cell lung cancer (NSCLC) who have experienced disease progression following chemoimmunotherapy (CIT). Lung cancer remains the leading cause of cancer-related death globally, and treatment options after CIT failure are limited. Gemcitabine has demonstrated immunostimulatory properties, including enhanced T-cell infiltration and reduced immunosuppressive cell populations, which may synergize with immune checkpoint inhibitors. Ivonescimab targets both PD-1 and VEGF pathways, potentially enhancing antitumor immune responses and inhibiting tumor angiogenesis. The trial aims to evaluate the objective response rate (ORR) according to RECIST v1.1 criteria. The combination therapy is expected to offer a novel and effective treatment strategy for patients with relapsed NSCLC, addressing a significant unmet medical need.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.